| MRSH |
Report |
Adjusted EPS (Q2 2026) |
BEAT |
pred ~$2.96 vs. cons $2.92 |
MEDIUM |
| MRSH |
Report |
Revenue (Q2 2026) |
IN-LINE |
pred ~$7.30B vs. cons $7.35B |
MEDIUM |
| MRSH |
Report |
Underlying (organic) revenue growth (Q2 2026) |
MISS |
pred ~3.2% vs. cons 3.6% |
MEDIUM |
| MRSH |
Guide |
FY2026 Adjusted EPS |
UNCHANGED |
guide ~$10.35 vs. cons $10.38 (FY2026) |
MEDIUM |
| MRSH |
Guide |
Fiduciary interest income |
LOWER |
guide ~$75M vs. cons $80M (Q3 2026) |
MEDIUM |
| MRSH |
Guide |
Full-year margin expansion (19th consecutive year) |
LOWER |
guide ~+25-30bps vs. cons ~+40bps (FY2026) |
LOW |
| MRSH |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.8% |
— |
MEDIUM |
| MRSH |
Return |
5-day cumulative residual |
-3.3% (FADE) |
A modest EPS beat driven largely by cost discipline/Thrive savings and fiduciary income timing masks a broader organic growth deceleration story (Guy Carpenter soft comps, commercial P&C rates still falling ~5%, Marsh Risk growth stalling), which analysts will read through into FY2026/2027 model cuts. Back-half-weighted margin guidance and continued fiduciary income decline give the sell-side room to trim out-period underlying growth and EPS estimates even after an in-line-to-slight-beat print, while the unresolved Greensill litigation overhang and mixed capital deployment commentary add incremental uncertainty. This combination typically produces an initial modest negative reaction that fades further over the following days as estimate revisions catch up, rather than stabilizing or reversing higher. |
MEDIUM |